Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

AbbVie Temettü

Temettü kriter kontrolleri 4/6

AbbVie şu anki getirisi 3.15% olan temettü ödeyen bir şirkettir. Bir sonraki ödeme tarihi olan 15th November, 2024 temettüden önceki tarihi 15th October, 2024 dir.

Anahtar bilgiler

3.2%

Temettü verimi

205%

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	15 Nov 24
Eski temettü tarihi	15 Oct 24
Hisse başına temettü	US$6.200
Hisse başına kazanç	US$3.00
Temettü verim tahmini	3.4%

Son temettü güncellemeleri

Recent updates

Yaklaşan Temettü Ödemesi

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ABBV şirketinin hisse başına düşen temettüsü son 10 yıldır istikrarlıydı.

Büyüyen Temettü: ABBV şirketinin temettü ödemeleri son 10 yıldır artış göstermektedir.

Piyasaya Karşı Temettü Getirisi

AbbVie Piyasaya Karşı Temettü Getirisi

ABBV temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ABBV)	3.2%
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (ABBV) (3 yıla kadar)	3.4%

Önemli Temettü: ABBV 'in temettüsü ( 3.15% ), US piyasasındaki temettü ödeyenlerin en alttaki %25'inden ( 1.42% ) daha yüksektir.

Yüksek Temettü: ABBV 'in temettüsü ( 3.15% ), US piyasasındaki temettü ödeyenlerin en üst %25'ine ( 4.33% ) kıyasla düşüktür.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Yüksek ödeme oranı ( 204.6% ) nedeniyle ABBV 'un temettü ödemeleri kazançlar tarafından yeterince karşılanmıyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Makul nakit ödeme oranı ( 61.6% ) ile ABBV 'un temettü ödemeleri nakit akışları ile karşılanmaktadır.

AbbVie Temettü

Temettü kriter kontrolleri 4/6

Anahtar bilgiler

Son temettü güncellemeleri

Upcoming dividend of US$1.55 per share

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

Upcoming dividend of US$1.55 per share

Recent updates

AbbVie Inc. to Report Q3, 2024 Results on Oct 30, 2024

AbbVie: Dividend Discount Model Suggests Large Valuation Risks

Abbvie Submits Biologics License Application to the FDA for Telisotuzumab Vedotin (Teliso-V) in Previously Treated Non-Small Cell Lung Cancer

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Second quarter dividend of US$1.55 announced

We Think AbbVie (NYSE:ABBV) Can Stay On Top Of Its Debt

AbbVie's VrayLAR®? (Cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia

Why AbbVie Remains One Of My Favorite Dividend Growers

Abbvie Receives Second Indication Approval from European Commission for Tepkinly® (Epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. Announces Ontario and Quebec Are First Provinces to Reimburse Subcutaneous Epkinly™ (Epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process

Executive Chairman recently sold US$12m worth of stock

Consensus EPS estimates fall by 10%

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) from FMR LLC and others.

AbbVie: Growth Is Still A Better Choice

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

AbbVie Inc. Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie's EPKINLY™ Receives First-Ever Time-Limited Reimbursement Recommendation by Canada's Drug Agency

Executive Chairman notifies of intention to sell stock

AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note

Abbvie Announces Appointment of Roopal Thakkar as Executive Vice President, Research & Development and Chief Scientific Officer

Upcoming dividend of US$1.55 per share

AbbVie Inc. to Report Q2, 2024 Results on Jul 25, 2024

AbbVie: A Hold Again (Rating Downgrade)

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV) acquired Celsius Therapeutics, Inc. for $250 million.

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

First quarter dividend of US$1.55 announced

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie: 5 Reasons That Make A Buy Case

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

AbbVie's Q1: Positive Surprise

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie: Great To Be Proven Wrong - Still Not A Buy

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

Upcoming dividend of US$1.55 per share

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

Yaklaşan Temettü Ödemesi

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin